Boehringer Ingelheim GmbH signed a licensing deal potentially worth more than $7 billion with China’s Sino Biopharmaceutical Limited and its subsidiaries for experimental cancer treatments.
Chung toi hien cong khai y chinh. Tao tai khoan mien phi de doc toan bo bai viet, luu, thao luan va ket noi voi boi canh thi truong va OSINT.